biOasis Technologies Ord Shs V.BTI.H

About The Neuramedy Deal

[JDavenport]

My momma told me many times that I don't have anything good to say that I shouldn't say anything at all. I don't pay much attention to that and I don't much like the Neuramedy deal. It makes sense on some level, but the numbers are awful. 

How can an xB3 license for Parkinson's disease (PD) be sold for an upfront payment that is so small that it's not material and reportable? How can any drug developed for such a huge indication like PD be worth only $70 million in milestones? (No mention of whether developmental or regulatory milestones are included. It looks like there are just commercial milestones and royalties, meaning way, way down the road.)

Even though the Neuramedy xB3 drug will have competing pipeline projects at both Neuramedy and Bioasis, it could still be a blockbuster drug that wouldn't exist without the key to the brain, xB3.

I have read several papers this morning that relate to PD, Neuramedy's approaches to PD and on related subjects. I just can't bring myself to write about it all today. I have a post underway but, look, there are reasons why the Bioasis share price jumped all the way back up to Monday's close, and has gone no further, so there's no hurry on this one.

I will say this. In the upcoming roadshow interviews, invitation only, I think you all should ask DrDR to explain why xB3 is turning out to be worth so little, because that looks like where this is going.

jd

[prophetoffact]

This post has been removed in accordance with Community Policy

[JDavenport]

poof, Parkinson's Disease wasn't licensed to Neuramedy. Neuramedy "...has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2." That's all the PR stated, poof. The next sentence about PD is unconsequencial.  xB3 has been licensed to Neuramedy for use with their

[prophetoffact]

This post has been removed in accordance with Community Policy

[JDavenport]

The bottom line is that Bioasis is getting peanuts in its deals. They're getting nothing compared to the value of the drug/disease combinations that xB3-Drugs can enable. Should we be looking for black helicopters? Why would Ladenburg Thalmann be looking for strategic opportunities and accretive mergers and acquisitions? Has Bioasis thrown in the towel on xB3? Is that what a deal like

[prophetoffact]

This post has been removed in accordance with Community Policy

[JDavenport]

You are a wonder, poof. Yesterday you were telling this forum that ETF trends are signalling that no amount of news can move Bioasis in bad markets. Today you're touting a deal you don't even come close to understanding. If it was good news, the market would have responded to it. The market did not respond. Now you're touting the deal, making excuses for it. Maybe this, maybe that

[prophetoffact]

This post has been removed in accordance with Community Policy

[JDavenport]

Lol,  investopedia gobbledypoof jd

[JDavenport]

I was looking at Neuramedy's efforts to cross the BBB with aptamer drug conjugates. Aptamers don't need to be made from cells lines. They can be manufactured, not so simply, but they can be chemically manufactured. They're then chemically conjugated with a payload, in this case, tomaralimab. So Neuramedy has to manufacture the monoclonal antibody and the aptamer, separately, and

[beenthere]

There you have it people!  ... direct from "the" Mouth himself!! ....It's better to do no deal than a bad deal. Sorry BUT I strongly disagree and I think Others will too! Over the years ( not me) but other posters have suggested that Bioasis " give" away one indication to get things started! Never happened. So give away or not here is a "chance" to get

[Cancundude]

The "mouth". Ya sounds about right. Back in the day we used to call him the chubby sheriff because he would police the boards. If you had a good argument he would criticize your spelling and or grammar. Bottom line , the mouth aka cubby sheriff has no life beyond these platforms thus his substantial efforts to validate himself constantly. Belittling others is his hallmark actually. Want